New Lows: ArQule, Inc. (NASDAQ:ARQL), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), TrovaGene Inc (NASDAQ:TROV)

ArQule, Inc (NASDAQ:ARQL) CEO Paolo Pucci purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, May 20th. The stock was purchased at an average cost of $1.42 per share, with a total value of $7,100.00. Following the transaction, the chief executive officer now directly owns 232,280 shares of the company’s stock, valued at approximately $329,838. ArQule, Inc. (NASDAQ:ARQL) stock performance was -2.76% … Continue reading New Lows: ArQule, Inc. (NASDAQ:ARQL), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), TrovaGene Inc (NASDAQ:TROV)

Mark Doerr05/2705/27

Biotech Stocks Touched New Lows: Onconova Therapeutics Inc (NASDAQ:ONTX), Array Biopharma (NASDAQ:ARRY), AVEO Pharmaceuticals (NASDAQ:AVEO), Infinity Pharmaceuticals (NASDAQ:INFI)

Onconova Therapeutics Inc (NASDAQ:ONTX)’s share price has entered into oversold territory with an RSI value of 19.3. The Zacks Consensus Estimate for Onconova Therapeutics Inc (NASDAQ:ONTX) for the full year period has improved 75 cents over the past two months to $-2.09 per share. Currently, Onconova Therapeutics Inc (NASDAQ:ONTX) has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get … Continue reading Biotech Stocks Touched New Lows: Onconova Therapeutics Inc (NASDAQ:ONTX), Array Biopharma (NASDAQ:ARRY), AVEO Pharmaceuticals (NASDAQ:AVEO), Infinity Pharmaceuticals (NASDAQ:INFI)

Mark Doerr04/0704/07

Biotech New Lows: AVEO Pharmaceuticals (NASDAQ:AVEO), Onconova Therapeutics (NASDAQ:ONTX), BioTime (NYSEMKT:BTX), Tetralogic Pharmaceuticals (NASDAQ:TLOG)

FDA publicly (justifiably) took down AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) when patients on its drug survived less long than those in the control group. Novo Nordisk found itself years behind competitors because the FDA insists on a heart safety study of its new insulin. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock performance was -3.21% in last session and finished the day at $1.51. Traded volume was 730,784.00million shares … Continue reading Biotech New Lows: AVEO Pharmaceuticals (NASDAQ:AVEO), Onconova Therapeutics (NASDAQ:ONTX), BioTime (NYSEMKT:BTX), Tetralogic Pharmaceuticals (NASDAQ:TLOG)

Colin Pettis03/3103/31

Healthcare Overbought Stocks: Pernix Therapeutics Holdings (NASDAQ:PTX), AVEO Pharmaceuticals (NASDAQ:AVEO), WellPoint Inc. (NYSE:WLP), Horizon Pharma (NASDAQ:HZNP)

Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) wants to start life with a new slate. It has taken several measures to wipe out the old issues. The company took care of two major worries. Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) stock performance was 10.43% in last session and finished the day at $5.93. Traded volume was 1.14 million shares in the last session and the average volume of … Continue reading Healthcare Overbought Stocks: Pernix Therapeutics Holdings (NASDAQ:PTX), AVEO Pharmaceuticals (NASDAQ:AVEO), WellPoint Inc. (NYSE:WLP), Horizon Pharma (NASDAQ:HZNP)

Jason Knox03/2403/24

Healthcare Unusual Volume: Palatin Technologies (NYSEMKT:PTN), AVEO Pharmaceuticals (NASDAQ:AVEO), Aastrom Biosciences (NASDAQ:ASTM), Merrimack Pharmaceuticals (NASDAQ:MACK)

Palatin Technologies (NYSE:PTN) major shareholder Bvf Partners L. P/Il sold 540,181 shares of Palatin Technologies stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $1.14, for a total transaction of $615,806.34. Palatin Technologies, Inc. (NYSEMKT:PTN) stock performance was 17.07% in last session and finished the day at $1.44. Traded volume was 3.33 million shares in the last … Continue reading Healthcare Unusual Volume: Palatin Technologies (NYSEMKT:PTN), AVEO Pharmaceuticals (NASDAQ:AVEO), Aastrom Biosciences (NASDAQ:ASTM), Merrimack Pharmaceuticals (NASDAQ:MACK)

Jayne Crisman03/2403/24

Top Losers: AVEO Pharmaceuticals (NASDAQ:AVEO), Santander Mexico Fincl Gp SAB (NYSE:BSMX), Oncothyreon Inc (NASDAQ:ONTY), Omeros Corporation (NASDAQ:OMER)

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported a fourth-quarter 2013 loss of 32 cents per share (excluding one-time expenses), narrower than the year-ago loss of 43 cents per share and the Zacks Consensus Estimate of a loss of 40 cents. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock performance was -6.08% in last session and finished the day at $1.70. Traded volume was 1.35million shares in the last session and … Continue reading Top Losers: AVEO Pharmaceuticals (NASDAQ:AVEO), Santander Mexico Fincl Gp SAB (NYSE:BSMX), Oncothyreon Inc (NASDAQ:ONTY), Omeros Corporation (NASDAQ:OMER)

Chris Lewis03/1703/17